These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10632971)

  • 1. Immunotherapy of Crohn's disease.
    Van Deventer SJ
    Scand J Immunol; 2000 Jan; 51(1):18-22. PubMed ID: 10632971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of Crohn's disease.
    van Montfrans C; Camoglio L; van Deventer SJ
    Mediators Inflamm; 1998; 7(3):149-52. PubMed ID: 9705600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
    Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
    J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
    Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
    Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance.
    Danese S; Pagano N; Angelucci E; Stefanelli T; Repici A; Omodei P; Daperno M; Malesci A
    Curr Med Chem; 2007; 14(14):1489-97. PubMed ID: 17584058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I; Lindley KJ; Londei M; Quaratino S
    Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 antibody treatment in Crohn's disease.
    Stronkhorst A; Tytgat GN; van Deventer SJ
    Scand J Gastroenterol Suppl; 1992; 194():61-5. PubMed ID: 1298050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
    Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
    Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease.
    Kirman I; Whelan RL; Nielsen OH
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):639-41. PubMed ID: 15201575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease.
    Shetty A; Forbes A
    Am J Pharmacogenomics; 2002; 2(4):215-21. PubMed ID: 12421092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
    van Hogezand RA; Verspaget HW
    Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease.
    Mouser JF; Hyams JS
    Clin Ther; 1999 Jun; 21(6):932-42; discussion 931. PubMed ID: 10440618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
    van Dullemen HM; van Deventer SJ; Hommes DW; Bijl HA; Jansen J; Tytgat GN; Woody J
    Gastroenterology; 1995 Jul; 109(1):129-35. PubMed ID: 7797011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.